<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) characterized by cytopenias, bone marrow and peripheral blood cell <z:mpath ids='MPATH_589'>dysplasia</z:mpath> is notoriously hard to treat </plain></SENT>
<SENT sid="1" pm="."><plain>Recent reclassification of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> as a myelodysplastic/myeloproliferative (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/MPS) disease rather than a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) by the World Health Organisation (WHO) has led to a review of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> patients treated with <z:chebi fb="0" ids="50131">decitabine</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Overall response rates (ORR) (complete response [CR]+partial response [PR]) in the subset of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> in one pivotal phase 3 trial (D-0007) and two phase 2 trials (PCH 95-11, PCH 97-19) <z:chebi fb="0" ids="50131">decitabine</z:chebi> were reviewed </plain></SENT>
<SENT sid="3" pm="."><plain>For consistency across trials, <z:hpo ids='HP_0000001'>all</z:hpo> <z:chebi fb="0" ids="50131">decitabine</z:chebi>-treated patients were evaluated using the phase 2 response criteria (CR was defined by normocellular bone marrow with &lt;5% blasts and <z:mpath ids='MPATH_458'>normal</z:mpath> Hgb, WBC, and platelet counts, and PR required 50% decrease in blast count, increases in Hgb by &gt;1.5 mmol/L, WBC count by &gt;1000, and platelet count by &gt;50,000) </plain></SENT>
<SENT sid="4" pm="."><plain>A total of 31 patients diagnosed with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> are included in this review </plain></SENT>
<SENT sid="5" pm="."><plain>Similar demographics and disease characteristics were observed in <z:hpo ids='HP_0000001'>all</z:hpo> three studies, with an average age of 70.2 years and 71% of patients male </plain></SENT>
<SENT sid="6" pm="."><plain>Baseline WBC of &gt;20,000 were observed in 8/28 (29%) patients and baseline bone marrow blasts &gt;5% in 11/28 (39%) patients </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> clinical responses were centrally reviewed </plain></SENT>
<SENT sid="8" pm="."><plain>The ORR was 25% (14% CR+11% PR) </plain></SENT>
<SENT sid="9" pm="."><plain>Hematologic improvement was observed in 11% of patients and stable disease in 39% of patients </plain></SENT>
<SENT sid="10" pm="."><plain>The <z:chebi fb="0" ids="50131">decitabine</z:chebi> adverse event profile seen in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> patients was similar to observations in other hematologic patient populations, with <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> and related infectious complications </plain></SENT>
<SENT sid="11" pm="."><plain>These data demonstrate encouraging activity for <z:chebi fb="0" ids="50131">decitabine</z:chebi> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>, and suggest that studies in other <z:mpath ids='MPATH_512'>myeloproliferative diseases</z:mpath> may be warranted </plain></SENT>
</text></document>